Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

AXSM - Axsome Therapeutics, Inc. So'nggi... | Finranks

Home

/

AXSM

A

Axsome Therapeutics, Inc. (AXSM)

NGM – Real vaqt narxi. Valyuta: USD

224.03

+7.56 (3.49%)

Yopilishda: May 12, 2026, 4:00 PM EDT

224.99

+0.96 (0.43%)

Bozor oldidan: May 13, 2026, 8:19 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer's Agitation Launch

Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer's Agitation Launch

Axsome Therapeutics NASDAQ: AXSM executives said the company is preparing for a June launch of AUVELITY in Alzheimer's disease agitation while continuing to expand its push in major depressive disorder, citing broad payer access, a larger sales force and what they described as a differentiated clinical profile.

Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Axsome Therapeutics Recognizes Mental Health Month

Axsome Therapeutics Recognizes Mental Health Month

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced its support for Mental Health Month alongside the broader mental health advocacy community. In recognition of this year's More Good Days Together theme, Axsome is sharing resources to support individuals affected by mental health conditions, their families, and the communities around them.

AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales

AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales

Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in May:

Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript

Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript

Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript

Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be Denied

Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be Denied

Axsome Therapeutics, Inc. is rated Hold, as revenue growth and pipeline promise are offset by sequential declines and ongoing losses. AXSM's Q1 revenues grew 57% year-on-year to $191m, but both Auvelity and Sunosi saw sequential sales declines. Management's peak revenue targets—over $18bn across the portfolio—appear highly ambitious given current product performance and competitive dynamics.

Videolar

No Data

There is no data to display

Press-relizlar

Axsome Therapeutics Recognizes Mental Health Month

Axsome Therapeutics Recognizes Mental Health Month

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced its support for Mental Health Month alongside the broader mental health advocacy community. In recognition of this year's More Good Days Together theme, Axsome is sharing resources to support individuals affected by mental health conditions, their families, and the communities around them.

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth AUVELITY ® 1Q 2026 net product sales of $153.2 million, representing 59% year-over-year growth SUNOSI ® 1Q 2026 net product revenue of $33.9 million, representing 34% year-over-year growth SYMBRAVO ® 1Q 2026 net product sales of $4.1 million AUVELITY approved for the treatment of agitation associated with dementia due to Alzheimer's disease NDA for AXS-12 for the treatment of cataplexy in narcolepsy submitted to the FDA AXS-20 (balipodect), potentially first-in-class, pre-Phase 3, PDE10A inhibitor for schizophrenia and Tourette syndrome, added to pipeline Company to host conference call today at 8:00 AM Eastern NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the first quarter of 2026 and provided a general business update. “Axsome had a tremendous start to 2026.

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem) resolving patent litigation related to Axsome's product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Alkem of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic version of SUNOSI in the United States. Under the terms of the settlement agreement, Axsome will grant Alkem a license to sell its generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type.

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively